Mining exomic sequencing data to identify mutated antigens recognized by adoptively transferred tumor-reactive T cells
- PMID: 23644516
- PMCID: PMC3757932
- DOI: 10.1038/nm.3161
Mining exomic sequencing data to identify mutated antigens recognized by adoptively transferred tumor-reactive T cells
Abstract
Substantial regressions of metastatic lesions have been observed in up to 70% of patients with melanoma who received adoptively transferred autologous tumor-infiltrating lymphocytes (TILs) in phase 2 clinical trials. In addition, 40% of patients treated in a recent trial experienced complete regressions of all measurable lesions for at least 5 years following TIL treatment. To evaluate the potential association between the ability of TILs to mediate durable regressions and their ability to recognize potent antigens that presumably include mutated gene products, we developed a new screening approach involving mining whole-exome sequence data to identify mutated proteins expressed in patient tumors. We then synthesized and evaluated candidate mutated T cell epitopes that were identified using a major histocompatibility complex-binding algorithm for recognition by TILs. Using this approach, we identified mutated antigens expressed on autologous tumor cells that were recognized by three bulk TIL lines from three individuals with melanoma that were associated with objective tumor regressions following adoptive transfer. This simplified approach for identifying mutated antigens recognized by T cells avoids the need to generate and laboriously screen cDNA libraries from tumors and may represent a generally applicable method for identifying mutated antigens expressed in a variety of tumor types.
Figures
![Figure 1](https://cdn.statically.io/img/www.ncbi.nlm.nih.gov/pmc/articles/instance/3757932/bin/nihms-455421-f0001.gif)
![Figure 2](https://cdn.statically.io/img/www.ncbi.nlm.nih.gov/pmc/articles/instance/3757932/bin/nihms-455421-f0002.gif)
![Figure 3](https://cdn.statically.io/img/www.ncbi.nlm.nih.gov/pmc/articles/instance/3757932/bin/nihms-455421-f0003.gif)
![Figure 4](https://cdn.statically.io/img/www.ncbi.nlm.nih.gov/pmc/articles/instance/3757932/bin/nihms-455421-f0004.gif)
Comment in
-
Immunotherapy: Adoptive cell therapy simplified.Nat Rev Clin Oncol. 2013 Jul;10(7):368. doi: 10.1038/nrclinonc.2013.85. Epub 2013 May 21. Nat Rev Clin Oncol. 2013. PMID: 23689751 No abstract available.
-
Tumor antigenicity revealed.Trends Immunol. 2014 Feb;35(2):47-8. doi: 10.1016/j.it.2014.01.001. Epub 2014 Jan 15. Trends Immunol. 2014. PMID: 24439426 Free PMC article.
Similar articles
-
Isolation of T-Cell Receptors Specifically Reactive with Mutated Tumor-Associated Antigens from Tumor-Infiltrating Lymphocytes Based on CD137 Expression.Clin Cancer Res. 2017 May 15;23(10):2491-2505. doi: 10.1158/1078-0432.CCR-16-2680. Epub 2016 Nov 8. Clin Cancer Res. 2017. PMID: 27827318 Free PMC article.
-
Isolation of neoantigen-specific T cells from tumor and peripheral lymphocytes.J Clin Invest. 2015 Oct 1;125(10):3981-91. doi: 10.1172/JCI82416. Epub 2015 Sep 21. J Clin Invest. 2015. PMID: 26389673 Free PMC article.
-
Efficient identification of mutated cancer antigens recognized by T cells associated with durable tumor regressions.Clin Cancer Res. 2014 Jul 1;20(13):3401-10. doi: 10.1158/1078-0432.CCR-14-0433. Clin Cancer Res. 2014. PMID: 24987109 Free PMC article.
-
Adoptive T-cell therapy using autologous tumor-infiltrating lymphocytes for metastatic melanoma: current status and future outlook.Cancer J. 2012 Mar-Apr;18(2):160-75. doi: 10.1097/PPO.0b013e31824d4465. Cancer J. 2012. PMID: 22453018 Free PMC article. Review.
-
The use of melanosomal proteins in the immunotherapy of melanoma.J Immunother. 1998 Jul;21(4):237-46. doi: 10.1097/00002371-199807000-00001. J Immunother. 1998. PMID: 9672845 Review.
Cited by
-
Targeting Pivotal Hallmarks of Cancer for Enhanced Therapeutic Strategies in Triple-Negative Breast Cancer Treatment-In Vitro, In Vivo and Clinical Trials Literature Review.Cancers (Basel). 2024 Apr 12;16(8):1483. doi: 10.3390/cancers16081483. Cancers (Basel). 2024. PMID: 38672570 Free PMC article. Review.
-
Advances in Therapeutic Cancer Vaccines, Their Obstacles, and Prospects Toward Tumor Immunotherapy.Mol Biotechnol. 2024 Apr 16. doi: 10.1007/s12033-024-01144-3. Online ahead of print. Mol Biotechnol. 2024. PMID: 38625508 Review.
-
Current Trends in Vaccine Development for Hereditary Colorectal Cancer Syndromes.Clin Colon Rectal Surg. 2023 Jul 31;37(3):146-156. doi: 10.1055/s-0043-1770383. eCollection 2024 May. Clin Colon Rectal Surg. 2023. PMID: 38606044 Review.
-
Novel insights into TCR-T cell therapy in solid neoplasms: optimizing adoptive immunotherapy.Exp Hematol Oncol. 2024 Apr 3;13(1):37. doi: 10.1186/s40164-024-00504-8. Exp Hematol Oncol. 2024. PMID: 38570883 Free PMC article. Review.
-
Untranslated regions (UTRs) are a potential novel source of neoantigens for personalised immunotherapy.Front Immunol. 2024 Mar 15;15:1347542. doi: 10.3389/fimmu.2024.1347542. eCollection 2024. Front Immunol. 2024. PMID: 38558815 Free PMC article.
References
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical